Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
PBS Snapshot
Cancer generics to suffer in October
PBS price cuts due in October will attack one of the last remaining areas in which generic companies have been able to increase their income from the PBS over the last year.
Open Forum
Lantus biosimilar approval heralds major change
The European approval of Abasria, a biosimilar for Sanofi's blockbuster insulin product Lantus, made by Boehringer Ingelheim and Eli Lilly, is a window to the future.
Pipeline Monitor
BI enters COPD combo lists
As other companies bring their new COPD combinations to market, Boehringer - threatened by change in the market - is stepping up development of its own.
Working Life
Sales still the pharma job engine
Despite Aussie pharma's sometimes gloomy outlook in the face of a slow growing PBS, sales jobs still dominate recruiters' advertising lists by a long way.
Approvals Action
Apotex eyes Lilly's $37m Alimta market
Apotex has taken the first steps towards competing for Lilly's $37.8 million market for lung cancer and mesothelioma drug Alimta.